
|Articles|December 12, 2012
Targeted therapy shows efficacy in advanced PCa
An orally bioavailable tyrosine kinase inhibitor demonstrated dramatic and rapid effects on advanced prostate cancer, according to researchers from the University of Michigan Comprehensive Cancer Center, Ann Arbor.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mark Tyson, MD shares promising BOND-003 results in papillary NMIBC
2
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
3
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
4
Modern frameworks for treating high-risk non–muscle invasive bladder cancer
5

















